A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies — CARTHIAE-1

Acute Lymphoblastic Leukemia, in Relapse Clinical Trial

Official title:
A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies

Status Not yet recruiting

Clinical Trial Summary

This is a phase l, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients. There will be three individual cohorts, defined by disease biology: pediatric ALL and aggressive pediatric NHL (Cohort 1), adult ALL (Cohort 2) and adult NHL/CLL (Cohort 3).

Clinical Trial Description

We will evaluate the safety of the MB-CART19.1 and determine the recommended dose levels for the Phase II clinical trial. Dose evaluation will start in Cohorts 1 and 2 with Dose Level 1 (5x10e5 CAR T cells/Kg) and in Cohort 3 with Dose Level 2 1x10e6 CAR T cells/Kg) , sparing Dose Level 1 . Each of the cohorts will evaluate the safety of the CAR-T cells. In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD. In Dose Level 3, three additional patients will be treated, if no DLT occurred. Dose Level 0 will be tested only if Dose Level 1 is not tolerable. ;

Study Design

Related Conditions & MeSH terms

Acute Lymphoblastic Leukemia, in Relapse
B-cell Lymphoma Recurrent
B-cell Lymphoma Refractory
Chronic Lymphocytic Leukemia Recurrent
Chronic Lymphocytic Leukemia Refractory
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Lymphoma
Lymphoma, B-Cell
Neoplasms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Recurrence

Clinical Trial Details

NCT number	NCT05705570
Study type	Interventional
Source	Hospital Israelita Albert Einstein
Contact	Nelson Hamerschlak, MD, PhH
Phone	+551121517248
Email	hamer@einstein.br
Status	Not yet recruiting
Phase	Phase 1
Start date	March 1, 2023
Completion date	December 1, 2028

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05066958` - Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT	Phase 1/Phase 2
Completed	`NCT04224571` - CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children	Phase 2
Recruiting	`NCT04888442` - Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL	Phase 1
Recruiting	`NCT04049383` - CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL	Phase 1
Not yet recruiting	`NCT05740449` - HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies	Phase 1/Phase 2
Not yet recruiting	`NCT05745714` - HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies	Phase 1/Phase 2
Not yet recruiting	`NCT06213636` - Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).	Phase 1/Phase 2
Recruiting	`NCT04603872` - CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies	Early Phase 1
Recruiting	`NCT04475731` - Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse	Phase 2
Not yet recruiting	`NCT05809284` - Determining the Mechanisms of Loss of CAR T Cell Persistence
Recruiting	`NCT03957915` - Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia	Early Phase 1
Terminated	`NCT03705507` - International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia	Phase 1/Phase 2
Recruiting	`NCT04605666` - CD19-CAR-T2 Cells for CD19 Positive Acute Lymphoblastic Leukemia	Phase 2
Recruiting	`NCT04325841` - Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children	Phase 2
Recruiting	`NCT04340167` - Study of Anti-CD22 CAR-T Cells Treating Leukemia Children	Phase 2
Active, not recruiting	`NCT04340154` - Study of Sequential CAR-T Cell Treating Leukemia Children	Phase 2
Recruiting	`NCT05310591` - Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence	Phase 1/Phase 2
Recruiting	`NCT05292664` - Venetoclax Basket Trial for High Risk Hematologic Malignancies	Phase 1
Recruiting	`NCT06316427` - Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Acute Lymphoblastic Leukemia/Lymphoma	Phase 1/Phase 2
Active, not recruiting	`NCT03573700` - Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia	Phase 1/Phase 2